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Abstract: Background 
KRAS mutations are the most frequent oncogenic aberration in lung 
adenocarcinoma. Due to differences in protein structure and GTPase 
activity, KRAS mutant isoforms shape tumor biology and therefore may 
influence the treatment response in non-small-cell lung cancer. This 
heterogeneity challenges the development of effective targeted therapies 
for KRAS-driven lung cancer.  
Methods 
Here, we systematically investigated MEK/ERK inhibitors sensitivity for 
different KRAS mutant isoforms. Then we developed an integrative 
pharmacogenomics analysis to identify potential targets in lung cancer 
with KRAS(G12C) mutation, the most frequent aberration in patients with 
primary or metastatic KRAS mutant non-small cell lung cancer.  We further 
validated our prediction by siRNA-mediated gene knockdown and TOPFlash 
reporter assay. 
Findings 
Our computational analysis identifies casein kinase 2A1 (CSNK2A1) as a 
mediator of MEK inhibitor resistance in KRAS(G12C) mutant cells which is 
not observed in cells with non-KRAS(G12C) mutations and in those 
harboring other oncogenic drivers as e.g. activating mutations in EGFR, 
BRAF, or NRAS. Knockdown of CSNK2A1 reduces proliferation, inhibits 
Wnt/β-catenin signalling and increases the anti-proliferative effect of 
selumetinib in KRAS(G12C) mutant lung cancer cells.  
Interpretation 
Our study suggested that accurate patients stratification will be 
necessary in order to observe significant benefit upon CK2 inhibition - 
alone or in combination - in a subset of patients with a favorable 
intratumoral genetic context. We provide a promising approach towards 
developing precision treatments for various subtypes of KRAS mutant lung 
cancer.  
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KRAS mutations are the most frequent oncogenic aberration in lung adenocarcinoma. Due to differences in 31 
protein structure and GTPase activity, KRAS mutant isoforms shape tumor biology and therefore may 32 
influence the treatment response in non-small-cell lung cancer. This heterogeneity challenges the 33 
development of effective targeted therapies for KRAS-driven lung cancer.  34 
Methods 35 
Here, we systematically investigated MEK/ERK inhibitors sensitivity for different KRAS mutant isoforms. 36 
Then we developed an integrative pharmacogenomics analysis to identify potential targets in lung cancer 37 
with KRAS(G12C) mutation, the most frequent aberration in patients with primary or metastatic KRAS 38 
mutant non-small cell lung cancer.  We further validated our prediction by siRNA-mediated gene 39 
knockdown and TOPFlash reporter assay. 40 
Findings 41 
Our computational analysis identifies casein kinase 2A1 (CSNK2A1) as a mediator of MEK inhibitor 42 
resistance in KRAS(G12C) mutant cells which is not observed in cells with non-KRAS(G12C) mutations 43 
and in those harboring other oncogenic drivers as e.g. activating mutations in EGFR, BRAF, or NRAS. 44 
Knockdown of CSNK2A1 reduces proliferation, inhibits Wnt/-catenin signalling and increases the anti-45 
proliferative effect of selumetinib in KRAS(G12C) mutant lung cancer cells.  46 
Interpretation 47 
Our study suggested that accurate patients stratification will be necessary in order to observe significant 48 
benefit upon CK2 inhibition - alone or in combination - in a subset of patients with a favorable intratumoral 49 
genetic context. We provide a promising approach towards developing precision treatments for various 50 
subtypes of KRAS mutant lung cancer.  51 
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 58 
Research in context 59 
Evidence before this study 60 
In NSCLC, different KRAS mutations have been identified according to the amino acid substitution which 61 
can affect drug sensitivity and tumor biology. 62 
Added value of this study 63 
We interrogated the publicly available pharmacogenomics dataset CGP to systematically unravel that 64 
cancer cells with different KRAS mutant isoforms differ in their drug sensitivities to MEK/ERK inhibitors. 65 
We further developed a computational pipeline to systematically identify novel therapeutic targets for 66 
KRAS(G12C) mutation, the most dominant KRAS mutation in lung cancer.   67 
Implications of all the available evidence 68 
Predicting novel therapeutic targets by considering the mutational heterogeneity of cancer histotypes will 69 
help to guide therapeutic decision-making and improve treatment outcomes. Our pipeline can potentially be 70 
extended to other mutant KRAS isoforms given that a large enough sample size is available for statistical 71 






Introduction  77 
The Kirsten rat sarcoma oncogene (KRAS) encodes for a small GTPase that couples growth factor 78 
signalling to the MAPK signalling cascade. Despite being an oncogene with a prevalence of 30% in non-79 
small cell lung cancer (NSCLC), the development of KRAS targeted therapies has been largely 80 
unsuccessful in the past. This is mainly due to the higher affinity of RAS for GTP 
1,2
. Very recently, the 81 
pharmacokinetic and pharmacodynamic improvement of direct G12C inhibitors has raised great excitement 82 
3
, leading to two clinical studies that are currently on-going 83 
(https://clinicaltrials.gov/ct2/results?cond=G12C&term=&cntry=&state=&city=&dist=). As an alternative, 84 
inhibitors targeting kinases downstream of KRAS, such as BRAF and MEK, have been developed which 85 
showed promising activity in metastatic melanoma but were less active in KRAS mutant NSCLC. 86 
Furthermore, drug efficacy is limited by the development of acquired resistance or KRAS copy number 87 
variations 
4-12
. Hence, there is still an unmet need to develop more efficacious targeted treatment strategies 88 
for KRAS mutant lung cancer. 89 
 90 
In NSCLC, different KRAS mutations have been identified according to the amino acid substitution which 91 
can affect drug sensitivity and tumor biology 
13,14
. The heterogenous behaviour of different KRAS 92 
mutations is due to differences in protein structure and GTPase activity 
15-17
 which needs to be considered 93 
when investigating potential targets for KRAS mutant lung cancer.  94 
 95 
Here, we perform a pan-cancer analysis to systematically investigate differences in treatment response to 96 
MEK inhibitors due to different KRAS mutational subtypes. An integrative pharmacogenomics analysis 97 
pipeline is then developed to identify potential targets in lung cancer with KRAS(G12C) mutation, the most 98 
frequent mutation (>40%) in patients with primary or metastatic KRAS mutant non-small cell lung cancer 99 
(NSCLC) 
17
. The most promising target predicted by this pipeline is casein kinase 2A1 (CSNK2A1) which 100 
encodes for the casein kinase 2 subunit alpha (CK2 alpha), a serine/threonine protein kinase that 101 
phosphorylates acidic proteins such as casein. Although there is strong evidence that CK2 plays a role in 102 
the pathogenesis of cancer 
18-20
 and several CK2 inhibitors have entered clinical trials, the role of 103 
CSNK2A1 as a therapeutic target in KRAS mutant lung cancer remains unknown to date. Our study links 104 
 5 
CSNK2A1 to Wnt/-catenin signaling and explores its potential as therapeutic target for treating KRAS 105 
mutant lung cancer. 106 
 107 
Materials & Methods 108 
Key Resources Table 109 
KRAS(G12C) mutant cell lines for integrative pharmacogenomics analysis  110 
Cell line KRAS Tissue TP53 
LU-65 G12C NSCLC_large cell E11Q 
NCI-H2030 G12C NSCLC_adenocarcinoma Q16L 
NCI-H2122 G12C NSCLC_adenocarcinoma C176F,Q16L 
LU-99A G12C NSCLC_large cell wt 
NCI-H1792 G12C NSCLC_adenocarcinoma ess_splice 
HCC-44 G12C NSCLC_adenocarcinoma p.R175L,S94* 
NCI-H23 G12C NSCLC_adenocarcinoma M246I 
NCI-H2291 G12C;G12V NSCLC_adenocarcinoma G154V 
NCI-H358 G12C NSCLC_adenocarcinoma wt 
SW1573 G12C NSCLC_adenocarcinoma wt 
IA-LM G12C NSCLC_large cell Q192* 
HOP-62 G12C NSCLC_adenocarcinoma ess_splice 
 111 
KRAS mutant cell lines for assays in vitro 112 
Cell line KRAS Tissue TP53 
Calu1 G12C NSCLC_ adenocarcinoma wt 
H2030 G12C NSCLC_adenocarcinoma Q16L 
A549 G12S NSCLC_adenocarcinoma wt 
 6 
H2009 G12A NSCLC_adenocarcinoma R273L 
 113 
Pharmacogenomics analysis to identify potential targets in KRAS(G12C) mutant lung cancer 114 
The Cancer Genome Project (CGP) at the Wellcome Trust Sanger Institute resulted in a large-scale, high-115 
throughput pharmacogenomic dataset for 1001 human cancer cell lines, including the mutation status of 116 
19,100 genes, genome-wide DNA copy number variation (CNV) status, mRNA expression profiling of 117 
17,419 genes, and pharmacological profiling for 267 anti-cancer drugs. The drug response is represented by 118 
the natural logarithm of the IC50 value, which corresponds to the half maximal inhibitory concentration of 119 
an anti-cancer drug. In this dataset, there are five MEK inhibitors including PD-0325901, selumetinib, CI-120 
1040, trametinib, and refamtinib, and two ERK inhibitors including FR-180204 and VX-11e. Among 137 121 
cancer cells harboring KRAS mutations, 35 cells are derived from lung cancer.  122 
 123 
We developed a computational pipeline to identify novel therapeutic targets for KRAS mutant lung cancer 124 
(Fig. 1). First, we started the analysis with CGP dataset. With respect to tumor heterogeneity generated 125 
from the different KRAS mutation isoforms, here, we only focused on lung cancer cell lines with 126 
KRAS(G12C) mutation, the most frequent among KRAS mutation isoforms in lung cancer. In total, we 127 
included 12 cell lines into our analyses.  MAPK signalling inhibitors, 5 types of MEK inhibitors including 128 
PD-0325901, selumetinib, CI-1040, trametinib, and refamtinib, and 2 types of ERK inhibitors including 129 
FR-180204 and VX-11e were included in this analysis. The expression of 17,420 genes was used to 130 
individually calculate their correlation with drug sensitivity. As expected, the high expression of some 131 
genes was significantly correlated with the decreased drug sensitivity of MEK inhibitors or ERK inhibitors. 132 
Of these, the genes with association with more than two MAPK signalling inhibitions were considered as 133 
the potential targets. Second, they were upregulated in KRAS(G12C) mutant Lung adenocarcinoma 134 
(LUAD) patients in comparison with normal samples in TCGA database. Optionally, the high expression of 135 
the genes has a poorer clinical prognosis. Third, we further filter the genes with selection criteria that 136 
required the genes to be part of cancer core pathways and to be known drug targets. Finally, by integrative 137 
analysis of the above-mentioned criteria, we identified potential targets for KRAS mutant lung cancer.  138 
 139 
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TCGA data analysis 140 
The RNA-seq and clinical data of LUAD patients were downloaded from TCGA cBioProtal 141 
(http://www.cbioportal.org/index.do). The abundance of each gene was quantified as RSEM value, which 142 
was evaluated by a statistical method RSEM (RNA-Seq by Expectation Maximization). RSEM uses a 143 
generative model of RNA-seq reads and the EM algorithm, taking read mapping uncertainty into account 144 
and achieving the most accurate abundance estimates 
21
. The statistical analysis of differentially expressed 145 
genes between cancer and normal samples was performed using DESeq2 
22
. LUAD patients were divided 146 
into high and low expressing group, based on the median value of gene expression across the patients. 147 
Kaplan-Meier test was used to compare the overall survival and cancer relapse between two groups. 148 
 149 
Cell lines  150 
The human lung cancer cell lines A549, H2030, H2009 and Calu1 were purchased from ATCC and grown 151 
at 37°C in RPMI medium supplemented with 10% fetal bovine serum (FBS), 100 μg/ml penicillin and 100 152 
units/ml streptomycin (complete medium). The cell lines were authenticated using the Promega GenePrint 153 
10 System at the RTSF Genomics Core at Michigan State University. All cell lines used in the study tested 154 
negative for Mycoplasma as determined by the Mycoplasma Plus PCR Primer Set (Agilent). 155 
 156 
Assessment of cellular proliferation 157 
Cells (1 × 10
3
) were seeded in 96-well plates in 100 μl RPMI media supplemented with 10% FBS and 158 
penicillin/streptomycin. The following day, plates were incubated in the IncuCyte ZOOM
TM
 (Essen 159 
BioScience) for real-time imaging, with three fields imaged per well under 10x magnification every two 160 
hours for a total of 120 hours. Data were analyzed using the IncuCyte Confluence version 1.5 software 161 
(Essen BioScience), which quantifies cell surface area coverage as confluence values. IncuCyte 162 
experiments were performed in triplicate. A representative growth curve is shown for each condition. 163 
 164 
Western blot analysis 165 
Cells from in vitro culture were lysed in RIPA lysis buffer (#89900 Thermo Fisher) supplemented with 166 
protease and phosphatase inhibitor cocktail tablets (Roche). The antibodies used for western blotting 167 
 8 
included those against: HSP90 (H114) (Santa Cruz Biotech Cat#sc-7947), phosphorylated Akt (Ser473) 168 
(Cell Signaling Cat#4060), Akt (Cell Signaling Cat#9272), phosphorylated ERK1/2 (Cell Signaling 169 
Cat#4370), ERK1/2 (Cell Signaling Cat#4695), phosphorylated MEK (Cell Signaling Cat#9154), MEK 170 
(Cell Signaling Cat#8727), phosphorylated S6 (Ser235/236) (Cell Signaling Cat#4858), S6 ribosomal 171 
protein (Cell Signaling Cat#2217), -catenin (Cell Signaling Cat#8480), p27 (Cell Signaling Cat#3688), 172 
cMyc (Cell Signaling Cat#2276), anti-rabbit IgG, HRP-linked secondary antibody Cell Signaling 173 
(Cat#7074P2), ECL Sheep anti-Mouse IgG, HRP-linked secondary antibody (GE Healthcare 174 
Cat#NA931V), ECL Donkey anti-Rabbit IgG, HRP-linked secondary antibody (GE Healthcare 175 
Cat#NA934V). Western blotting showed in the manuscript are representative of at least three independent 176 
experiments. 177 
 178 
SiRNA-mediated gene knockdown 179 
Cells (1,5x10
6
) were seeded in a 10cm plate and incubated overnight at 37°C. On the next day, media was 180 
replaced by antibiotic free full media and the mixture of siRNA (scrambled, CSNK2A1, Dharmacon) at a 181 
final concentration of 20nM together with DharmaFECT 1 was added after allowing 30min of complex 182 
formation in serum-free media. Knockdown efficacy was assessed by Western blot and qRT-PCR after 183 
48hrs of transfection. For treatment experiments cells were harvested and re-seeded after 48hrs of siRNA 184 
treatment and treated with selumetinib for another 24 to 96hrs. 185 
 186 
TOPFlash reporter assay 187 
Cells (1,5x10
6
) were seeded in a 10cm plate and incubated overnight at 37°C. On the next day, cells were 188 
transiently transfected with 1g of M50 Super 8x TOPFlash reporter plasmid, 100ng of a pRL Renilla 189 
Luciferase control reporter plasmid (Promega) and FuGENE HD (Promega). M50 Super 8x TOPFlash was 190 
a gift from Randall Moon (Addgene plasmid #12456). After 24hrs, cells were washed with PBS and full 191 
media was added for another 24hrs without or with Mek inhibitor (selumetinib, 1m). Luciferase activity 192 




Cancer cells with different KRAS mutant isoforms differ in their drug sensitivities to MEK/ERK 196 
inhibitors 197 
We first interrogated the publicly available pharmacogenomics dataset CGP, which includes mutational and 198 
pharmacological profiles of >1000 human cancer cell lines treated with 265 anti-cancer drugs 
23
. Drug 199 
sensitivities are represented by the natural logarithm of the drug’s IC50 value. To investigate MEK/ERK 200 
inhibitors sensitivity for different KRAS mutant isoforms, we grouped all cancer cells based on their KRAS 201 
mutation status, and then used the Kruskal-Wallis H-test to compare drug sensitivities between multiple 202 
groups and the t-test to compare drug sensitivities between two groups. 203 
  204 
KRAS mutant cancer cell lines were divided into 12 groups, respectively, with A146T, G12A, G12C, 205 
G12D, G12R, G12S, G12V, G13C, G13D, K117N, Q61H, or Q61L mutations. We found that MEK/ERK 206 
inhibitors drug sensitivities vary in cell lines with different KRAS mutations, including CI-1040, 207 
refametinib (RDEA119), PD-0325901, selumetinib, trametinib, and VX-11e (Fig. 2). Cells lines with G12R 208 
mutation were in general more sensitive to MEK inhibitors in comparison with other types of KRAS 209 
mutations (Fig. 2a-f). To address the question if also the tissue of origin influences response to MAPK 210 
pathway inhibition, we furthermore investigated the effect of different KRAS mutations on drug 211 
sensitivities in the two major cancer histotypes of lung and pancreatic cancer. Differences in MEK/ERK 212 
inhibitors sensitivities across the different types of KRAS mutations were observed in both cancer types, 213 
being pancreatic cancer cells with G12R mutation (Additional file 1: Figure S1a-c) and lung cancer cells 214 
with G12A mutation (Additional file 1:  Figure S1d-e) most sensitive to MEK inhibition, respectively.  215 
 216 
We surveyed the datasets of primary LUAD patients from TCGA and metastatic LUAD patients from 217 
MSK-IMPACT to investigate the prevalence of different KRAS mutational isoforms (Fig. 3). 75 (33%) of 218 
patients with primary LUAD and 241 (27%) of patients with metastatic LUAD patients harbor KRAS 219 
mutations, respectively. In total, we observed ten different types of KRAS mutations, including G12C, 220 
G12D, G12A, G12F, G12R, G12S, G12V, G12Y, Q61L, D33E, in the primary LUAD TCGA dataset 221 
(Additional file 2: Table S1). Whereas KRAS(G12C) is the dominant mutation in patients with primary 222 
KRAS mutant NSCLC (48.00%, Fig. 3a), patients with metastatic LUAD exhibit a more complex pattern 223 
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of KRAS mutations. Among 19 types of KRAS mutations, 11 types (A146T, A146V, A59T, AG59GV, 224 
G13C, G13D, G13E, G13R, G13V, Q61R, and T58I) are exclusively observed in patients with metastatic 225 
LUAD but not in primary tumors (Fig. 3b, Additional file3: Table S2). In metastatic LUAD patients, the 226 
KRAS(G12C) mutation is also the most prevalent one (42.74%), followed by G12V (15.35%) and G12D 227 
(15.35%) mutations. 228 
 229 
Pharmacogenomics analysis to identify potential targets in lung cancer harboring KRAS(G12C) 230 
mutations 231 
Our above-mentioned analysis of the CGP dataset suggests that cancer cell lines with different KRAS 232 
mutations exhibit different sensitivities to MAPK pathway inhibition. In the present analysis, we focused 233 
on lung cancer cell lines with KRAS(G12C) mutation, the most dominant KRAS mutation in lung cancer. 234 
In our analysis, a total of 12 cell lines were included (see Methods). We developed a computational 235 
pipeline to identify novel therapeutic targets for KRAS mutant lung cancer (Fig. 1). In a first step of this 236 
pipeline, 1212 genes with association with more than two inhibitors of MAPK signalling were considered 237 
as potential targets. In a second step, using the TCGA database, we selected 494 genes which are 238 
upregulated in LUAD patients and are associated with poor survival. Finally, we narrowed down the 239 
number of genes by requiring them to be part of core cancer pathways as well as to be known drug targets. 240 
This algorithm finally led to the identification of 14 potential therapeutic targets for KRAS mutant lung 241 
cancer (Fig. 1d), including AARS2, ALKBH2, CARS, CDK8, COMP, CSNK2A1, DARS, EPRS, HDAC1, 242 
IARS2, MAPK8, PARS2, RPL8 and YARS (Additional file 4:  Table S3). 243 
 244 
Among the 14 candidate genes identified by our pharmacogenomics analysis, CSNK2A1 was ranked as the 245 
most promising gene. CSNK2A1 encodes for a protein which is a component of the highly conserved 246 
serine/threonine protein kinase CK2 alpha. CK2 alpha itself is part of various pathways relevant for cancer 247 
cell biology among them Wnt (Fig. 4a) and NF-kappa B signaling 
20
. This is especially relevant as there is 248 
an increased interest for CSNK2 as a therapeutic target in ongoing clinical trials 
24
. The association of 249 
CSNK2A1 expression and reduced MEK/ERK inhibitors sensitivity was repeatedly observed for 4 different 250 
MEK inhibitors, including 2 replicate datasets for refametinib and selumetinib (Fig. 4b). Importantly, 251 
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LUAD patients or LUAD patients with KRAS(G12C) mutation showed an increased expression of 252 
CSNK2A1 in comparison with normal lung tissue (Fig. 4c, p=1.35e-18). Moreover, LUAD patients with 253 
high CSNK2A1 expression had a trend towards poorer overall survival (Additional file 5:  Figure S2).  254 
 255 
Correlation of CSNK2A1 levels and MEK inhibitor resistance is neither observed in non-256 
KRAS(G12C) mutant lung and pancreatic cancer cells, nor in lung cancer with EGFR, BRAF or 257 
NRAS mutations 258 
We next investigated if the correlation between CSNK2A1 expression and MEK inhibitor resistance can 259 
also be observed in non-KRAS(G12C) mutant cancer cells. As KRAS(G12V) mutations represent the 260 
second most frequent mutation in LUAD, nine KRAS(G12V) mutant lung cancer cell lines from CGP were 261 
included in the statistical analysis. No correlation was found between CSNK2A1 expression and drug 262 
sensitivity to 7 MEK inhibitors in KRAS(G12V) mutant lung cancer cells (Fig. 5a). Due to the limited 263 
sample size for other non-KRAS(G12C) mutations, we pooled the remaining lung cancer cells with non-264 
KRAS(G12C) mutations, for which no positive correlation between CSNK2A1 expression and drug 265 
sensitivity was observed (Fig. 5b). As KRAS(G12V) and KRAS(G12D) mutations occur more frequently 266 
in pancreatic cancer, we therefore also investigated the correlation of CSNK2A1 levels and MEK inhibitor 267 
resistance in KRAS(G12V) or KRAS(G12D) mutant pancreas cancer cells. This analysis also showed no 268 
correlation between CSNK2A1 expression and drug sensitivity (Fig. 5c,d).  269 
 270 
We furthermore investigated if there is any correlation between CSNK2A1 expression and MEK inhibitor 271 
resistance in lung cancer cell lines with other oncogenic mutations affecting the MAPK signaling pathway 272 
as for example BRAF, EGFR, or NRAS. However, our analysis showed no correlation between CSNK2A1 273 
expression and MEK inhibitor resistance for BRAF- (Fig. 6a), EGFR- (Fig. 6b), or NRAS-mutant (Fig. 6c) 274 
lung cancer cells. Cell lines we used for the analysis were in Additional file 6: Table S4. 275 
 276 
CSNK2A1 knockdown reduces proliferation and Wnt/-catenin reporter activity in KRAS(G12C) 277 
mutant lung cancer cells, and increases the anti-proliferative effect of selumetinib  278 
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We selected two KRAS(G12C) mutant lung cancer cell lines (Calu1 and H2030) and two non-279 
KRAS(G12C) mutant cell lines (A549 and H2009) to investigate the effect of siRNA-mediated CSNK2A1 280 
knockdown on cell proliferation and efficacy of MAPK pathway inhibition with 1µM of selumetinib. 281 
Knockdown of CSNK2A1 (Fig. 7a) alone significantly decreased proliferation of KRAS(G12C) mutant 282 
cells Calu1 (Fig. 7b) and H2030 (Fig. 7c) and increased the anti-proliferative activity of simultaneous MEK 283 
inhibition in Calu1 cells (Fig. 7b). These effects were not observed in non-KRAS(G12C) mutant lung 284 
cancer cell lines (Fig. 7d-f).  285 
 286 
As casein kinases have previously been connected to the drug resistance mediating Wnt/-catenin pathway 287 
25,26
, we therefore investigated if CSNK2A1 influences Wnt/-catenin signaling in KRAS(G12C) mutant 288 
lung cancer. We used gene expression profiles of LUAD patients (TCGA) and cancer cell lines (CCLE) 
27
 289 
and categorized samples into CSNK2A1 high and low expressing groups. Deseq2 
28
 was applied to call 290 
differentially expressed genes between the two groups. Gene set enrichment analysis (GSEA) 
29
 was further 291 
employed to determine the pathways enriched by a pre-ranked list of all genes, which were sorted by the 292 
statistical significance of differential expression defined by the Deseq2 analysis. GSEA showed that the 293 
Wnt signaling pathway was significantly enriched in the CSNK2A1 high expressing group in CCLE (Fig. 294 
8a, p=0.008) and TCGA (Fig. 8b, p=0.014).  295 
 296 
To support our computational findings, we also investigated the differences in Wnt/-catenin signaling 297 
parameters between KRAS(G12C) and KRAS(non-G12C) cell lines in vitro. After 24hrs of selumetinib 298 
treatment, accumulation of the cell cycle inhibitor p27 upon CSNK2A1 knockdown was relatively 299 
increased in KRAS(G12C) mutant Calu1 and H2030 cells compared to KRAS(non-G12C) A549 and 300 
H2009 cells (Fig. 8c). This suggests that Calu1 and H2030 cells are more dependent on CSNK2A1 to 301 
overcome MEK inhibitor induced growth arrest. This is also in agreement with the stronger anti-302 
proliferative effect of CSNK2A1 knockdown itself in cells with KRAS(G12C) mutation (Additional file 7: 303 
Figure S3, Fig. 7b,e). Furthermore, transient transfection of the Wnt/TCF reporter plasmid 8xTOPFlash 304 
showed stronger reduction of reporter activity in Calu1 cells with KRAS(G12C) mutation than in 305 
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KRAS(G12S) mutant A549 cells upon CSNK2A1 knockdown and upon simultaneous treatment with 306 
selumetinib (Fig. 8d).  307 
 308 
Discussion 309 
In this study, we used pharmacogenomics data to systematically unravel the heterogeneity of responses to 310 
MAPK pathway inhibition due to different KRAS mutation isoforms. Subsequently, we developed a 311 
pharmacogenomics analysis pipeline to identify novel targets for the subgroup of KRAS(G12C) mutant 312 
lung cancer. Our computational pipeline identified a correlation between CSNK2A1 expression and MEK 313 
inhibitor resistance in KRAS(G12C) mutant cells, a finding that was exclusively observed in this 314 
mutational subset of lung cancer cells, but not in KRAS(non-G12C) mutant cells and neither in tumor cells 315 
harboring other oncogenic mutations as e.g. EGFR, BRAF, or NRAS. This suggests that the correlation 316 
between CSNK2A1 expression and MEK inhibitor resistance may depend on the context of KRAS(G12C) 317 
mutation in lung cancer. A pan-cancer analysis of the TCGA dataset showed that CSNK2A1 is upregulated 318 
in a wide range of cancers (Additional file 8: Figure S4) and that pancreatic cancer patients with high 319 
intratumoral CSNK2A1 expression have a worse overall and relapse-free survival (Additional file 9: Figure 320 
S5). 321 
 322 
CSNK2A1 encodes for a protein that is a component of the highly conserved serine/threonine protein 323 
kinase CK2 alpha. Previous studies have identified CSNK2 as an oncogene when overexpressed in mice, 324 
playing a key role in the pathogenesis of cancer, including breast, lung, colon, and prostate cancer, as well 325 
as hematologic malignancies 
19,20,30
. Moreover, a cancer context-dependent effect of CK2 on signaling 326 




, NF-κB 20, and PTEN/PI3K/Akt-PKB 32,33 has been 327 
described in the past. In the Wnt pathway, CK2 acts by phosphorylating and stabilizing Dvl and β-catenin 328 
and promotes T-cell factor/lymphoid enhancer-binding factor (TCF) DNA binding in the nucleus (Fig. 4a). 329 
Based of these observations, CK2 has recently arisen as a promising candidate for targeted therapy, with 330 
two CK2 inhibitors in ongoing clinical trials 331 
(https://clinicaltrials.gov/ct2/results?cond=&term=CK2&cntry=&state=&city=&dist=). Our results suggest 332 
that accurate patients stratification will likely be necessary in order to observe significant benefit upon CK2 333 
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inhibition - alone or in combination - in a subset of patients with a favorable intratumoral genetic context. 334 
 335 
In agreement with our computational results, CSNK2A1 knockdown significantly reduced the proliferation 336 
of KRAS(G12C) mutant lung cancer cells, an effect that was not observed in cells with non-G12C KRAS 337 
mutations (Fig. 7). This identifies CSNK2A1 as an interesting target per se in KRAS(G12C) mutant 338 
NSCLC cell lines. Furthermore, simultaneous CSNK2A1 knockdown and MEK inhibition with selumetinib 339 
increased the anti-proliferative effect of selumetinib in KRAS(G12C) mutant but not in KRAS(non-G12C) 340 
mutant cells. Mechanistically, our analysis including transient 8xTOPFlash reporter transfection shows that 341 
CSNK2A1 mediates TCF transcriptional activity in KRAS(G12C) mutant lung cancer (Fig. 8d). The 342 
importance of CSKN2A1 for Wnt signaling is also supported by our gene-set enrichment analysis (GSEA) 343 
of the CCLE and TCGA datasets which show significant enrichment for the Wnt signaling pathway (Fig. 344 
8a, b).  345 
 346 
For a given oncogene, different types of nonsynonymous or indel variants impact differently on the 347 
biological function of the respective protein. This results in different oncogenic activities in cancer cells 348 
with different oncogenic mutations and challenges the development of effective targeted therapies. 349 
Therefore, predicting novel therapeutic targets by considering the mutational heterogeneity of cancer 350 
histotypes will help to guide therapeutic decision-making and improve treatment outcomes. Although the 351 
pharmacogenomics approach suggested by us here was applied to KRAS(G12C) mutant lung cancer cells, 352 
this pipeline can potentially be extended to other mutant KRAS isoforms given that a large enough sample 353 
size is available for statistical analysis.  354 
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Figures and Tables Legend 448 
Figure 1. A pharmacogenomics analysis identifies the potential therapeutic targets in KRAS-mutant 449 
lung cancer cells. A, pharmacogenomics data and analysis for identifying genes whose high expression 450 
associates with decreased drug sensitivity. B, TCGA data analysis for evaluating the expression of genes in 451 
lung adenocarcinoma (LUAD) patients as well as their correlation with clinical prognosis. C, Cancer core 452 
pathway and DrugBank information for further investigating the biological relevance of candidate genes. D, 453 
Overall integrative analysis for determining the potential therapeutic targets.  454 
 455 
Figure 2. Pan-cancer analysis of drug sensitivities to MEK/ERK inhibitors, including CI-1040, 456 
refametinib, PD-0325901, selumetinib, trametinib, and VX-11e, in cancer cells with different types of 457 
KRAS mutations. The p value of the multiple-groups comparison is indicated. A symbol * denotes the 458 
pairwise comparison with p value smaller than 0.05. 459 
 460 
Figure 3. Frequencies of different KRAS mutations in the primary LUAD patients in TCGA dataset 461 
and the metastatic LUAD patients in MSK-IMPACT dataset. KRAS(G12C) is the most common 462 
mutation (>40%) across LUAD patients. 463 
 464 
Figure 4. A pharmacogenomics analysis identifies CSNK2A1 as a potential therapeutic target in 465 
KRAS-mutant lung cancer cells. A, The protein encoded by CSNK2A1 is a serine/threonine protein 466 
kinase, which is involved in various cellular processes, including the Wnt signalling pathway. B, High 467 
expression of CSNK2A1 is associated with decreased drug sensitivity to MEK inhibitors refametinib, 468 
selumetinib, CI-1040, and trametinib. C, CSNK2A1 expression is significantly higher in LUAD compared 469 
to normal lung tissue.  470 
 471 
 19 
Figure 5. (A) Expression of CSNK2A1 in lung cancer cell lines with KRAS(G12V) mutation, the second 472 
most frequent mutation in lung cancer, is not correlated with drug sensitivity to MEK inhibitors. (B) 473 
Expression of CSNK2A1 in other non-G12C mutant lung cancer cell lines, is not positively correlated with 474 
drug sensitivity to MEK inhibitors. (C) Expression of CSNK2A1 in pancreatic cancer cell lines with 475 
KRAS(G12V) mutation, the most frequent mutation in pancreatic cancer, is not correlated with drug 476 
sensitivity to MEK inhibitors. (D) Expression of CSNK2A1 in pancreatic cancer cell lines with 477 
KRAS(G12D) mutation, the second most frequent mutation in pancreatic cancer, is not correlated with 478 
drug sensitivity to MEK inhibitors. 479 
 480 
Figure 6. Expression of CSNK2A1 is not correlated with MEK inhibitor sensitivity in lung cancer cell 481 
lines with BRAF (A), EGFR (B) or NRAS (C) mutations. 482 
 483 
Figure 7. CSNK2A1 Knockdown reduces the proliferation of KRAS(G12C) mutant lung cancer cells 484 
and increases the anti-proliferative effect of the MEK inhibitor selumetinib. (A) Western blot analysis 485 
of CSNK2A1 protein in KRAS(G12C) mutant cell lines Calu1 and H2030 transfected with scrambled or 486 
CSNK2A1 targeting siRNA without or with simultaneous selumetinib (1μm) treatment. Growth rates of 487 
Calu1 (B) and H2030 (C) transfected with scrambled (black and purple) or CSNK2A1 targeting siRNA 488 
(red and grey) without or with simultaneous selumetinib (1μm) treatment. Phase-contract images are 489 
shown at the bottom. (D) Western blot analysis of CSNK2A1 protein in KRAS(G12S) mutant cell line 490 
A549 and in KRAS(G12A) mutant cell lines H2009 transfected with scrambled or CSNK2A1 targeting 491 
siRNA without or with simultaneous selumetinib (1μm) treatment. Growth rates of A549 (E) and H2009 492 
(F) transfected with scrambled (black and purple) or CSNK2A1 targeting siRNA (red and grey) without or 493 
with simultaneous selumetinib (1μm) treatment. Phase-contract images are shown at the bottom.  494 
 495 
Figure 8. CSNK2A1 knockdown inhibits the activation of Wnt/-catenin signaling in KRAS(G12C) 496 
mutant lung cancer cells. GSEA analysis based on CCLE lung cancer cells  (A) and TCGA LUAD 497 
patients (B) with KRAS mutation shows that Wnt signaling pathway is enriched in tumors with high 498 
CSNK2A1 expression. (C) Western blot analysis shows increased p27 induction upon selumetinib 499 
 20 
treatment in siCSNK2A1 treated Calu1 and H2030 compared to A549 and H2209. (D) Reporter activity of 500 
Wnt/TCF reporter assay in Calu1 KRAS(G12C) and A549 KRAS(G12S). Student t-test are performed, 501 
with a symbol *, **, and **** respectively representing the comparison with p value smaller than 0.05, 502 
0.01 and 0.0001. 503 
 504 
Additional file1: Figure S1. Pan-cancer analysis investigates the drug sensitivity to MEK/ERK inhibitors, 505 
including CI-1040, refametinib, PD-0325901, selumetinib, trametinib, and VX-11e, of the different types 506 
of KRAS mutations in pancreatic cancer and lung cancer cell lines.  The p value of the multiple-groups 507 
comparison is given. A symbol * denotes the pairwise comparison with p value smaller than 0.05. 508 
 509 
Additional file2: Table S1. The prevalence of different KRAS mutational isoforms in primary LUAD 510 
patients 511 
 512 
Additional file3: Table S2. The prevalence of different KRAS mutational isoforms in metastatic 513 
LUAD patients 514 
 515 
Additional file4: Table S3. Fourteen potential therapeutic targets for KRAS mutant lung cancer. 516 
 517 
Additional file5: Figure S2. LUAD patients with higher expression of CSNK2A1 tend to have shorter 518 
overall survival. 519 
 520 
Additional file6: Table S4. Information of cell lines with KRAS(G12C) mutation in lung cancer, with 521 
KRAS(G12V) mutation in lung cancer, with KRAS(non-G12C) mutation in lung cancer, with 522 
KRAS(G12V) mutation in pancreatic cancer, with KRAS(G12D) mutation in pancreatic cancer, with 523 




Additional file7: Figure S3. Growth rates of Calu1 KRAS(G12C) (a) and A549 KRAS(G12S) (b) 527 
transfected with scrambled or CSNK2A1 targeting siRNA without or with simultaneous selumetinib 528 
(1umettreatment. Student t-test are performed, with a symbol *, ****, and n.s. respectively representing the 529 
comparison with p value smaller than 0.05, 0.0001 and greater than 0.05. 530 
 531 
Additional file8: Figure S4. Expression of CSNK2A1 is upregulated in a wide range of cancers.  532 
 533 
Additional file9: Figure S5. Pancreatic cancer patients with higher expression of CSNK2A1 534 




Pharmacogenomics data (CGP dataset)
* 12 KRAS(G12C) mutant lung cell lines
* 6 MEK inhibitors, 2 ERK inhibitors
























TCGA data (LUAD patients)
* 36 KRAS(G12C) mutant patients
* 576 samples (517 patients vs. 59 normal)
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Click here to download Figure: Additional file1_Figure S1.pdf
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Table S1. The prevalence of different KRAS mutational isoforms in primary LUAD patients
Supplementary Table S1





















Table S2. The prevalence of different KRAS mutational isoforms in metastatic LUAD patients
Supplementary Table S2
drugId drugName target_gene target_pathwaygene cells Spearman pval adjPval
1372 Trametinib MEK1, MEK2 ERK MAPK signalingAARS2 KRASG12C 0.657 0.02 0.397945292
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingAARS2 KRASG12C 0.615 0.033 0.533334017
1060 PD-0325901 MEK1, MEK2 ERK MAPK signalingALKBH2 KRASG12C 0.915 0 0
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingALKBH2 KRASG12C 0.721 0.019 0.387727888
1498 selumetinib MEK1, MEK2 ERK MAPK signalingCARS KRASG12C 0.811 0.001 0.031604522
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingCARS KRASG12C 0.79 0.002 0.061137987
1372 Trametinib MEK1, MEK2 ERK MAPK signalingCARS KRASG12C 0.748 0.005 0.138871421
1062 selumetinib MEK1, MEK2 ERK MAPK signalingCARS KRASG12C 0.81 0.015 0.330350852
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingCARS KRASG12C 0.673 0.033 0.533334017
1498 selumetinib MEK1, MEK2 ERK MAPK signalingCDK8 KRASG12C 0.769 0.003 0.088607594
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingCDK8 KRASG12C 0.601 0.039 0.584552683
1015 CI-1040 MEK1, MEK2 ERK MAPK signalingCOMP KRASG12C 0.817 0.007 0.184018247
1498 selumetinib MEK1, MEK2 ERK MAPK signalingCOMP KRASG12C 0.692 0.013 0.299435549
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingCSNK2A1 KRASG12C 0.79 0.002 0.061137987
1062 selumetinib MEK1, MEK2 ERK MAPK signalingCSNK2A1 KRASG12C 0.881 0.004 0.115864071
1498 selumetinib MEK1, MEK2 ERK MAPK signalingCSNK2A1 KRASG12C 0.741 0.006 0.163150558
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingCSNK2A1 KRASG12C 0.782 0.008 0.205302231
1372 Trametinib MEK1, MEK2 ERK MAPK signalingCSNK2A1 KRASG12C 0.587 0.045 0.624014981
1060 PD-0325901 MEK1, MEK2 ERK MAPK signalingDARS KRASG12C 0.697 0.025 0.461067753
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingDARS KRASG12C 0.697 0.025 0.461067753
1498 selumetinib MEK1, MEK2 ERK MAPK signalingEPRS KRASG12C 0.881 0 0
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingEPRS KRASG12C 0.811 0.001 0.031604522
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingEPRS KRASG12C 0.818 0.004 0.115864071
1372 Trametinib MEK1, MEK2 ERK MAPK signalingEPRS KRASG12C 0.692 0.013 0.299435549
263 FR-180204 ERK ERK MAPK signalingHDAC1 KRASG12C 0.72 0.008 0.205302231
262 VX-11e ERK ERK MAPK signalingHDAC1 KRASG12C 0.615 0.033 0.533334017
1060 PD-0325901 MEK1, MEK2 ERK MAPK signalingIARS2 KRASG12C 0.818 0.004 0.115864071
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingIARS2 KRASG12C 0.721 0.019 0.387727888
262 VX-11e ERK ERK MAPK signalingMAPK8 KRASG12C 0.762 0.004 0.115864071
263 FR-180204 ERK ERK MAPK signalingMAPK8 KRASG12C 0.699 0.011 0.261266107
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingPARS2 KRASG12C 0.72 0.008 0.205302231
1498 selumetinib MEK1, MEK2 ERK MAPK signalingPARS2 KRASG12C 0.587 0.045 0.624014981
1526 RDEA119 MEK1, MEK2 ERK MAPK signalingRPL8 KRASG12C 0.72 0.008 0.205302231
1498 selumetinib MEK1, MEK2 ERK MAPK signalingRPL8 KRASG12C 0.636 0.026 0.467907815
1372 Trametinib MEK1, MEK2 ERK MAPK signalingRPL8 KRASG12C 0.608 0.036 0.56542678
1372 Trametinib MEK1, MEK2 ERK MAPK signalingYARS KRASG12C 0.678 0.015 0.330350852
1498 selumetinib MEK1, MEK2 ERK MAPK signalingYARS KRASG12C 0.671 0.017 0.361519728
1014 RDEA119 MEK1, MEK2 ERK MAPK signalingYARS KRASG12C 0.636 0.048 0.637656047
Supplementary Table S3
Table S4-1. Information of cell lines with KRAS(G12V) mutation in lung cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
NCI-H727 724855_lung KRAS (missense:c.35G>T:p.G12V) (Missense:c.496_497insACAAGCAGT:p.Q165_S166insYKQ)
NCI-H2444 1298356_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.707A>G:p.Y236C)
LCLC-97TM1 946361_lung KRAS (missense:c.35G>T:p.G12V) (frameshift:c.102delC:p.L35fs*9)
NCI-H2291 724874_lung KRAS (missense:c.35G>T:p.G12V)(missense:c.34G>T:p.G12C)(missense:c.461G>T:p.G154V)
SHP-77 724872_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.528C>G:p.C176W)
COLO-668 910692_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.1039G>C:p.A347P)(missense:c.733G>T:p.G245C)
SW900 724879_lung KRAS (missense:c.35G>T:p.G12V) (nonsense:c.499C>T:p.Q167*)
NCI-H441 908460_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.473G>T:p.R158L)
COR-L23 687780_lung KRAS (missense:c.35G>T:p.G12V) wt
Table S4-2. Information of cell lines with KRAS(non-G12C) mutation in lung cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
NCI-H1355 724866_lung KRAS (missense:c.37G>T:p.G13C) (missense:c.853G>A:p.E285K)
Calu-6 724859_lung KRAS (missense:c.181C>A:p.Q61K) (nonsense:c.586C>T:p.R196*)
NCI-H727 724855_lung KRAS (missense:c.35G>T:p.G12V) (Missense:c.496_497insACAAGCAGT:p.Q165_S166insYKQ)
NCI-H1944 1240185_lung KRAS (missense:c.38G>A:p.G13D) wt
SK-LU-1 909721_lung KRAS (missense:c.35G>A:p.G12D) (missense:c.578A>G:p.H193R)
NCI-H650 722066_lung KRAS (missense:c.182A>T:p.Q61L) (missense:c.492G>T:p.K164N)
A427 910851_lung KRAS (missense:c.35G>A:p.G12D) wt
EMC-BAC-2 1503370_lung KRAS (missense:c.35G>C:p.G12A) wt
NCI-H2444 1298356_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.707A>G:p.Y236C)
NCI-H1573 908472_lung KRAS (missense:c.35G>C:p.G12A) (missense:c.743G>T:p.R248L)
NCI-H647 1240191_lung KRAS (missense:c.38G>A:p.G13D) (ess_splice:c.782+1G>T:p.?)
LCLC-97TM1 946361_lung KRAS (missense:c.35G>T:p.G12V) (frameshift:c.102delC:p.L35fs*9)
SHP-77 724872_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.528C>G:p.C176W)
NCI-H460 905943_lung KRAS (missense:c.183A>T:p.Q61H) wt
A549 905949_lung KRAS (missense:c.34G>A:p.G12S) wt
COLO-668 910692_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.1039G>C:p.A347P)(missense:c.733G>T:p.G245C)
NCI-H2009 724873_lung KRAS (missense:c.35G>C:p.G12A) (missense:c.818G>T:p.R273L)
SW900 724879_lung KRAS (missense:c.35G>T:p.G12V) (nonsense:c.499C>T:p.Q167*)
NCI-H1734 722058_lung KRAS (missense:c.37G>T:p.G13C) (missense:c.818G>T:p.R273L)
NCI-H2347 687820_lung KRAS (missense:c.57G>T:p.L19F) wt
NCI-H1155 908467_lung KRAS (missense:c.183A>T:p.Q61H) (missense:c.818G>A:p.R273H)
NCI-H441 908460_lung KRAS (missense:c.35G>T:p.G12V) (missense:c.473G>T:p.R158L)
COR-L23 687780_lung KRAS (missense:c.35G>T:p.G12V) wt
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Table S4-3. Information of cell lines with KRAS(G12V) mutation in pancreatic cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
DAN-G 1290797_pancreas KRAS (missense:c.35G>T:p.G12V) (ess_splice:c.972_993+16del38:p.?)
QGP-1 1298534_pancreas KRAS (missense:c.35G>T:p.G12V) (frameshift:c.293delC:p.P98fs*25)
PANC-03-27 925346_pancreas KRAS (missense:c.35G>T:p.G12V) (ess_splice:c.375+5G>T:p.?)
KP-3 1298219_pancreas KRAS (missense:c.35G>T:p.G12V) (frameshift:c.450_451insC:p.P153fs*28)
MZ1-PC 753595_pancreas KRAS (missense:c.35G>T:p.G12V) (frameshift:c.626_627delGA:p.R209fs*6)
CFPAC-1 906821_pancreas KRAS (missense:c.35G>T:p.G12V) (missense:c.724T>C:p.C242R)
PA-TU-8902 1298526_pancreas KRAS (missense:c.35G>T:p.G12V) (missense:c.526T>A:p.C176S)
CAPAN-1 753624_pancreas KRAS (missense:c.35G>T:p.G12V) (missense:c.476C>T:p.A159V)
Capan-2 910915_pancreas KRAS (missense:c.35G>T:p.G12V) wt
YAPC 909904_pancreas KRAS (missense:c.35G>T:p.G12V) (missense:c.536A>G:p.H179R)
HuP-T4 907286_pancreas KRAS (missense:c.35G>T:p.G12V) (missense:c.764T>C:p.I255T)
PA-TU-8988T 1240201_pancreas KRAS (missense:c.35G>T:p.G12V) (missense:c.844C>T:p.R282W)
Table S4-4. Information of cell lines with KRAS(G12D) mutation in pancreatic cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
HPAF-II 724869_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.451C>T:p.P151S)
PANC-02-03 1298475_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.743G>A:p.R248Q)
PANC-04-03 1298476_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.733G>A:p.G245S)
PANC-08-13 925347_pancreas KRAS (missense:c.35G>A:p.G12D) wt
PL4 1298533_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.797G>T:p.G266V)
KP-1N 1298216_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.818G>A:p.R273H)
HPAC 1298136_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.559G>C:p.G187R)
SW1990 910907_pancreas KRAS (missense:c.35G>A:p.G12D) (inframe:c.572_574delCTC:p.P191delP)
PANC-10-05 925348_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.764T>A:p.I255N)
AsPC-1 910702_pancreas KRAS (missense:c.35G>A:p.G12D) (frameshift:c.403delT:p.C135fs*35)
SUIT-2 1240219_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.818G>A:p.R273H)
SU8686 1240218_pancreas KRAS (missense:c.35G>A:p.G12D) (missense:c.1079G>T:p.G360V)(missense:c.733G>A:p.G245S)
Table S4-5. Information of cell lines with BRAF mutation in lung cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
NCI-H1651 910900_lung BRAF (missense:c.1125A>T:p.E375D) (missense:c.527G>A:p.C176Y)
NCI-H1395 684681_lung BRAF (missense:c.1406G>C:p.G469A) wt
NCI-H2227 688018_lung BRAF (missense:c.958G>T:p.A320S) (ess_splice:c.783-2A>C:p.?)
SW1271 1299062_lung BRAF (missense:c.2048G>A:p.S683N) (missense:c.830G>T:p.C277F)
IST-SL2 753565_lung BRAF (ess_splice:c.608+1G>T:p.?) (nonsense:c.880G>T:p.E294*)
NCI-H1666 908473_lung BRAF (missense:c.1397G>T:p.G466V) wt
NCI-H1755 908475_lung BRAF (missense:c.1406G>C:p.G469A) (missense:c.725G>T:p.C242F)
NCI-H2087 724834_lung BRAF (missense:c.1789C>G:p.L597V) (missense:c.469G>T:p.V157F)
NCI-H2405 687821_lung BRAF (inframe:c.1454_146916>A:p.L485_P490>Y)(missense:c.818G>A:p.R273H)
CAL-12T 753540_lung BRAF (missense:c.1397G>T:p.G466V) (missense:c.404G>T:p.C135F)
Supplementary Table S4_2
Table S4-6. Information of cell lines with EGFR mutation in lung cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
NCI-H1355 724866_lung EGFR (missense:c.3477G>C:p.Q1159H) (missense:c.853G>A:p.E285K)
NCI-H1975 924244_lung EGFR (missense:c.2369C>T:p.T790M)(missense:c.2573T>G:p.L858R)(missense:c.818G>A:p.R273H)
MS-1 753594_lung EGFR (missense:c.771A>T:p.E257D) (missense:c.730G>A:p.G244S)
NCI-H1650 687800_lung EGFR (inframe:c.2235_2249del15:p.E746_A750del)(ess_splice:c.673-2A>G:p.?)
PC-14 753608_lung EGFR (inframe:c.2235_2249del15:p.E746_A750del)(missense:c.743G>A:p.R248Q)
HCC-827 1240146_lung EGFR (inframe:c.2236_2250del15:p.E746_A750del)(inframe:c.652_654delGTG:p.V218delV)
SHP-77 724872_lung EGFR (missense:c.2102A>G:p.Q701R) (missense:c.528C>G:p.C176W)
NCI-H2291 724874_lung EGFR (missense:c.1774G>T:p.V592F) (missense:c.461G>T:p.G154V)
H3255 1247873_lung EGFR (missense:c.2573T>G:p.L858R) (ess_splice:c.560-1G>A:p.?)
NCI-H1793 908463_lung EGFR (missense:c.932G>T:p.C311F) (missense:c.818G>A:p.R273H)(nonsense:c.625A>T:p.R209*)
NCI-H1568 1298348_lung EGFR (missense:c.3379G>A:p.D1127N) (missense:c.536A>G:p.H179R)
PC-3 [JPC-3] 1240202_lung EGFR (inframe:c.2236_2244delGAATTAAGA:p.L747_E749delLRE)(missense:c.844C>T:p.R282W)
Table S4-7. Information of cell lines with NRAS mutation in lung cancer
Cell line COSMIC_ID&tissue Gene Mutation TP53
NCI-H1048 687995_lung NRAS (frameshift:c.59_60delCA:p.T20fs*11) (missense:c.817C>T:p.R273C)(frameshift:c.140delC:p.P47fs*76)
COR-L279 910937_lung NRAS (missense:c.14A>G:p.K5R) (ess_splice:c.376-4_384delacagTACTCCCCT:p.?)
SW1271 1299062_lung NRAS (missense:c.182A>G:p.Q61R) (missense:c.830G>T:p.C277F)
NCI-H1299 724831_lung NRAS (missense:c.181C>A:p.Q61K) (ess_splice:c.1_9543021>AAG:p.?)
NCI-H2087 724834_lung NRAS (missense:c.181C>A:p.Q61K) (missense:c.469G>T:p.V157F)
NCI-H2135 1298352_lung NRAS (missense:c.181C>A:p.Q61K) (missense:c.830G>T:p.C277F)
HCC-15 1240143_lung NRAS (missense:c.557G>T:p.C186F)(missense:c.181C>A:p.Q61K)(missense c.77 A>T:p.D259V)
NCI-H2347 687820_lung NRAS (missense:c.182A>G:p.Q61R) wt
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